1L Non-small Cell Lung Cancer (NSCLC) w/ EGFR exon 20 insertion mutations
AVBPArriVentCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Firmonertinib in 1L Non-small Cell Lung Cancer (NSCLC) w/ EGFR exon 20 insertion mutations. The expected timing is based on the latest available company guidance and may change.
FURVENT Ph3 Trial. 7/21/25- Breakthrough Therapy Designation. Topline Ph3 data expected in Early 2026 12/22/25:- FURVENT Ph3 trial enrolled 398 patients; no interim analysis planned; topline data still expected Early 2026. 03/05/26:- FURVENT Ph3 topline firmonertinib monotherapy data in 1L EGFR exon 20 NSCLC expected Mid-2026. 03/17/26:- AACR 2026 firmonertinib crystal-structure poster scheduled Apr 21, 2026. 05/11/26:- FURVENT Ph3 frontline EGFR exon 20 NSCLC topline monotherapy data still projected for Mid-2026. 08/12/26:- FURVENT Phase 3 topline data in first-line EGFR exon 20 insertion NSCLC is expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.